Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HQ SPCLT PHARMA
HQ SPCLT PHARMA has fifteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
Summary for Hq Spclt Pharma
| US Patents: | 6 |
| Tradenames: | 18 |
| Ingredients: | 12 |
| NDAs: | 15 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-004 | Jun 22, 2018 | RX | Yes | No | 9,649,296 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-005 | Dec 6, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-002 | Oct 21, 2015 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hq Spclt Pharma | LINEZOLID | linezolid | SOLUTION;INTRAVENOUS | 207001-001 | Jul 7, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 6,096,331 | ⤷ Start Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014143845 | ⤷ Start Trial |
| Australia | 2016403510 | ⤷ Start Trial |
| Canada | 2906031 | ⤷ Start Trial |
| European Patent Office | 2948379 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 6/2019 | Austria | ⤷ Start Trial | PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721 |
| 0984957 | 300483 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105 |
| 2603514 | SPC/GB19/021 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REGISTERED: UK EU/1/18/1334 (NI) 20181120; UK PLGB 16239/0061 20181120 |
| 0300652 | C300117 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
